Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

Cardiovascular Patient Preference Data Inform Payer Coverage Decisions

Edwards Transcatheter Aortic Valve Replacement Patient Preference Study Supports Payer Coverage Decisions
 

Source
Medical Device Innovation Consortium

Link
How Can Medical Device Manufacturers Make Best Use of Patient Preference Information?
 

Description of Case Study

In 2018, Edwards Lifesciences conducted a patient preference study with individuals with severe aortic stenosis to systematically quantify and compare preferences between transcatheter aortic valve replacement (TAVR) and surgical valve replacement, building on patient-reported experiences. The study demonstrated a strong patient preference for TAVR among low-risk patients despite similar clinical outcomes and was used to inform coverage and reimbursement discussions with payers to support expanded access to TAVR.
 

Quick Facts

Organization name: Edwards Lifesciences
Organization type: large medtech company (250-plus employees)
Product category: therapeutic device or technology
Region(s) of patient engagement activities: North America: Canada, United States
Total product life cycle stage(s): coverage/payment

 

Product Type(s)

medical device:

  • implantable device
     

Product Medical Specialty Area(s)

  • cardiovascular
     

Stakeholders

  • medtech company: internal market access teams
  • patients and caregivers, patient organizations
  • regulators
  • health technology assessors
  • payers (public/private)
     

Methods and Sources of Patient Input

  • patient advocacy organizations
  • patient preference information/studies
     

Impact of Patient Engagement

The study resulted in a publication that served as a resource to provide robust patient preference data for coverage and reimbursement consideration in payer decision-making. Though the Centers for Medicare & Medicaid Services did not have a process or infrastructure to evaluate and weigh the data, the Ontario Health Technology Advisory Committee applied the patient preference data to support public funding of TAVR for low-risk patients in Ontario in 2020. Additional impacts of patient engagement include:

  • Demonstrated the value of patient preference evidence beyond clinical outcomes: The study showed that patients strongly preferred TAVR even when clinical outcomes were similar to surgery, providing evidence that patient preferences can complement traditional clinical evidence in access and reimbursement decisions.
  • Supported payer understanding of patient-valued outcomes: The study translated patient experiences and treatment preferences into quantitative evidence that could be considered alongside clinical and economic evidence during reimbursement evaluations.
     

Lessons Learned

  • Plan patient preference studies early: Early planning helps ensure that patient preference evidence is available when it can inform regulatory, payer, and product development decisions.
  • Partner with patient organizations: Collaborating with patient advocacy organizations can improve patient recruitment and retention, supporting successful execution of patient preference studies.
  • Engage decision-makers throughout the process: Involving regulators, payers, and other decision- makers early helps align with their needs and build confidence in the study’s methodology and findings.
  • Use validated, patient-centered methods: Employing validated patient preference methodologies and clear, patient-friendly questions helps capture meaningful and reliable preference data.
  • Demonstrate the value of patient preference studies: Given the investment required for typical patient preference studies (approximately $150,000–$400,000), demonstrating the value of the evidence relative to study costs is important for organizational support.
  • Disseminate findings broadly: Sharing results internally and externally helps maximize the use of patient preference evidence in product research and development as well as regulatory and payer decision-making.